FDA, Payers & Hackers: The Three Forces That Make or Break a Launch

Most medtech founders picture their launch as a single finish line: clear the FDA, and the rest follows. Christian Espinosa and Edwin Lindsay have watched enough launches break to know it does not work that way. A device can fail at the FDA, at the payer, or at the firewall, and increasingly it fails at more than one at once.

This Open Door Salon conversation, a continuation of a discussion host Lori Ellis started with them at MedTech World, brings together two people who see the failure points from different angles. Christian Espinosa is the founder and CEO of Blue Goat Cyber, a medical-device cybersecurity firm that has supported more than 250 FDA submissions. Edwin Lindsay is principal consultant and managing director at CS Lifesciences, a regulatory and quality consultancy that guides devices from concept through clearance and market launch. The episode is made possible by MedTech World.

The cybersecurity deficiency letters are exploding

The most immediate signal is the volume of FDA cybersecurity deficiencies. In the past two weeks alone, Espinosa said, Blue Goat had roughly ten discovery meetings with prospects that had received cybersecurity deficiencies from the FDA. Some of those lists run 37 pages. Manufacturers rarely grasp the scale of work required to close them, which usually means re-engaging the software team, a long delay, and a lot of unplanned cost.

The clock makes it worse. The FDA gives 180 days to respond. Espinosa estimates about 80 percent of companies fix things inside that window; the other 20 percent have to file an entirely new submission. And as Lindsay pointed out, cybersecurity is often the tip of the iceberg: if the fix means redesigning the device, the verification and validation testing has to be redone too.

Why vibe coding has no place in a regulated device

Espinosa drew a hard line on vibe coding, the practice of generating software through AI prompts. It is fine for proving a concept, he said, but it pulls in unnecessary libraries that each carry vulnerabilities, and the FDA does not recognize it as a proven methodology. The governing standard, IEC 62304, does not reference it. He put the stakes plainly: he once asked an innovator using vibe code for an implantable whether he would trust that device in his own grandmother if her life depended on it. The answer was no.

For investors trying to tell a safe bet from a dangerous one, Espinosa offered a simple diagnostic: ask which software-development standards the team follows. No answer is the red flag.

Patient safety, not data protection

The framing both men returned to is that medical-device cybersecurity is a patient-safety discipline, not an IT one. Many investors still think the risk is data protection, Lindsay said, but it is really about patient safety. If someone can hack the device, the question is not what data they can steal, it is what harm they can cause a patient. He described a live risk assessment on an in-vitro diagnostic: delay a result past 24 hours for a septic patient, or alter it, and the patient can die. When a founder leads with HIPAA and stored records, he treats it as a sign they are solving the wrong problem.

China is a signal, not a verdict

On China, Espinosa resisted the easy answer. Country of origin is a signal, he said, not a control. A device built in America is not automatically more secure than one built in China; the same firmware analysis, software bill of materials, and supply-chain scrutiny apply either way. A Chinese device that passed detailed firmware analysis and penetration testing, he argued, is more trustworthy than an American one nobody examined. The harder problem is the subcontractor layer most companies never audit for cyber controls, and cases like a Chinese prospect that had quietly modified the firmware on its device’s 4G chip with no convincing reason.

FDA readiness in 2026 means proof, not checkboxes

Asked what FDA readiness actually looks like now, Espinosa said the mindset shift is that cybersecurity is quality. It used to sit adjacent to the quality management system; now it is part of it. The second shift is evidence. The FDA and the healthcare delivery organizations buying the device no longer accept a checked box; they ask for the artifacts that prove the process was followed. And any device with a way to connect to it, whether Bluetooth, NFC, or a USB port, is a cyber device, however much a manufacturer wants to argue otherwise.

Reimbursement that starts after clearance is already too late

The third force is the payer. Both men urged founders to bring reimbursement strategy into product design as early as possible. Companies routinely run expensive clinical studies that satisfy the FDA but not the payer, Lindsay said, and getting a reimbursement code can take longer than getting the product cleared. The most expensive mistake he has seen: a company that assumed its device would fit an existing code, got its clearance, then spent five or six years unable to sell at scale while it chased reimbursement, surviving door to door in the private market. A new level of scrappy, as Ellis put it.

Why the work is personal

Both men came to healthcare through the patient side. Espinosa, an Iron Man triathlete, was diagnosed with six blood clots by a Doppler ultrasound and founded Blue Goat Cyber after realizing his life had depended on a medical device working correctly. Lindsay’s grandson had emergency surgery for a pinched aorta at six days old, pulling him toward helping startups bring pediatric devices to market. The throughline of the conversation is that in medtech, the launch and the patient are the same problem seen from opposite ends.